RICHMOND, British Columbia, Nov. 7, 2006 (PRIMEZONE) -- BioCurex Inc. (OTCBB:BOCX) today commented on the PSA velocity study published on Nov. 1 in the Journal of the National Cancer Institute (NCI). In this study, the authors studied the increase of PSA (“velocity”) in serum samples from 980 men monitored since 1958.
